To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information

I Agree

Chronic Idiopathic Constipation Treatment Market

Chronic Idiopathic Constipation Treatment Market Analysis By Type (Normal-transit Constipation, Slow-transit Constipation), By Therapy (Pharmacological Therapies, Non-pharmacological Therapies), By Treatment (Medication, Surgery), By Drug (Serotonin-4 (5-Ht4) Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants), By Route of Administration, By End User & By Region - Global Market Insights 2023 to 2033

Analysis of Chronic Idiopathic Constipation Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Chronic Idiopathic Constipation Treatment Market Outlook (2023 to 2033)

The global chronic idiopathic constipation treatment market is set to increase from a valuation of US$ 9.4 billion in 2023 and reach US$ 19.7 billion by the end of 2033, Expanding swiftly at a CAGR of 7.5%.

A common functional bowel condition known as chronic idiopathic constipation (CIC) can be defined when a person experiences difficult, infrequent, and/or unsatisfactory defecation. Sedentary lifestyle, rising use of anti-inflammatory drugs, and a sharp drop in dietary fiber consumption are some of the causes that are increasing the number of people suffering from chronic idiopathic constipation.

  • Millions of people worldwide suffer from chronic idiopathic constipation, a very prevalent functional bowel illness. According to the National Center for Biotechnology Information, CIC affects 10% to 17% of the world's population and is more common in women and older people.

Normal-transit constipation and slow-transit constipation are two types of chronic idiopathic constipation. The type of constipation that is typically encountered by the individual is normal-transit constipation. Stool frequency and transit time through the colon are both normal, but patients still report feeling constipated. Patients in this group complain of hard stools, bloating, abdominal pain, or both.

Slow-transit constipation can be identified by decreased large intestine motility, which is brought on by enteric nerve abnormalities. Constipation and excessive soiling are just two examples of the chronic issues brought on by the exceptionally slow-transit of waste through the large intestine.

In the next ten years, the demand for constipation treatment is expected to rise as a result of high R&D spending for the creation of novel drugs for chronic idiopathic constipation, advancements in healthcare facilities, increasing rate of the geriatric population, shifting dietary patterns, and high fast food consumption. Another factor that is projected to fuel the growth of the chronic idiopathic constipation treatment market is the increasing simplicity and accessibility of over-the-counter medications for chronic idiopathic constipation.

Report Attributes

Details

Market Size (2023E)

US$ 9.4 Billion

Forecasted Market Value (2033F)

US$ 19.7 Billion

Global Market Growth Rate (2023 to 2033)

7.5% CAGR

Leading Regional Market

North America

Share of Constipation Treatment Market (2023)

88.2%

Key Companies Profiled

  • Bayer AG
  • Allergan
  • Bausch Health
  • Sanofi
  • Takeda Pharmaceutical Company
  • Sebela Pharmaceuticals
  • Ironwood Pharmaceuticals, Inc.
  • Albireo Pharma, Inc.
  • Sucampo Pharmaceuticals, Inc. (Mallinckrodt)
  • Janssen Pharmaceuticals, Inc.
  • Synergy Pharmaceuticals Inc.
  • Shandong Luoxin Pharmaceutical Group Stock Co., Ltd
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Abbott Laboratories
  • GlaxoSmithKline Plc
  • Troikaa Pharmaceuticals Ltd
  • Lupin
  • East West Pharma
  • Ferring B.V.
  • Albireo Pharma, Inc.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Dynamics are Expected to Drive the Sales of Chronic Idiopathic Constipation Solutions?

“Constant Developments in CIC Treatment Procedures”

Chronic idiopathic constipation was initially treated with a combination of medication review, dietary changes, and patient education. Several non-prescription chronic idiopathic constipation treatments, such as fiber supplementation, have gained popularity, while prescription treatments are anticipated to see widespread use in the coming 10 years.

Evidence suggests that soluble fibers such as psyllium, as opposed to insoluble fibers such as bran, can help people with chronic idiopathic constipation. Because of the notable improvement in overall symptoms and stool consistency that has resulted from the greater intake of soluble fibers, the market for chronic idiopathic constipation treatments is heavily favouring the use of soluble fibers in empiric fiber therapy. Thus, the demand for non-prescription treatments is growing rapidly due to their high adoption rates globally.

“Older Population Mostly Experience Chronic Idiopathic Constipation Problems”

Rising population of geriatric patients is the main factor in the increasing demand for CIC treatment products. The chronic non-cancer pain these patients experience is treated with analgesics such as hydromorphone, codeine, morphine, etc., which have severe side effects on the digestive tract and cause a huge demand for chronic idiopathic constipation medications.

The elderly population over 65 is more vulnerable to chronic illnesses. Constipation-related problems are five times more common in elderly people than in younger adults. Poor food, a lack of adequate fluids in the diet, inactivity, the use of particular medications to treat other medical illnesses, and unfavourable bowel habits are some of the factors leading to constipation in the elderly population.

  • According to the World Health Organization Facts of 2021, between the years 2015 to 2050, the percentage of the world's population 60 and older is expected to nearly double, from 12% to 22%.
  • By 2030, 1 in every 6 persons on the earth is likely to be of 60 years of age or older.
  • By 2050, there are likely to be 1.4 billion people in the world who are 60 years of age and older, up from 1 billion in 2020.

Why Do Patients Prefer Natural Chronic Idiopathic Constipation Treatment Options?

“Preference for Home Remedies Due to High Overall Treatment Costs”

More so than the treatment, patients rely on home remedies. Treatment is connected with medications, dietary, and lifestyle modifications that increase the overall treatment costs. Bowel incontinence carries a heavy social stigma that is linked to mental distress and prevents the disease from being properly diagnosed. Other issues impeding sales of chronic idiopathic constipation drugs are poor reimbursement policies and a lack of knowledge about the treatment of constipation in emerging countries.

  • Around 81% expense of treating chronic idiopathic constipation, according to a study issued in the American Journal of Managed Care, is attributed to medical services, such as outpatient care and visits to prescribers.
  • According to several studies, persistent constipation patients with abdominal symptoms pay 1.6 times more at the pharmacy than those without those symptoms.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Will New Market Players Be Able to Penetrate the Chronic Idiopathic Constipation Treatment Market?

“Each Patient Has Different Issues – Need to Meet Unique Needs Opens up New Opportunities”

CIC is a chronic condition that requires long-term management, and patients often require different treatment approaches based on the severity of their symptoms. The treatment options for CIC include laxatives, fiber supplements, prokinetics, stool softeners, and other prescription medications. In recent years, there has been a growing demand for newer and more effective treatment options for CIC, as some patients do not respond well to existing therapies or may experience side effects.

The chronic idiopathic constipation treatment market offers several opportunities for new manufacturers to enter. Here are some potential benefits :

  • Unmet Needs: Despite the availability of various treatment options, there are still unmet needs in the management of CIC. Some patients do not respond well to existing therapies or may experience side effects, leading to the demand for newer and more effective treatment options. New manufacturers can capitalize on these unmet needs by developing innovative medicines that address these gaps in the market.
  • Market Segmentation: The market for chronic idiopathic constipation treatments is diverse, with different patient populations requiring different treatment approaches. For example, elderly patients, pediatric patients, and patients with specific comorbidities may have unique treatment requirements. New manufacturers can focus on specific patient populations and develop tailored treatment options to cater to their needs, thereby creating a major market position for themselves.
  • Technological Innovation: Technology has the potential to revolutionize the treatment of CIC. There is a growing interest in developing novel drug delivery systems, such as oral films, nanoparticles, and microspheres, which can enhance the efficacy and safety of chronic idiopathic constipation treatments. New chronic idiopathic constipation drug manufacturers with expertise in advanced drug delivery technologies can bring innovative products with user-friendly designs and disrupt the traditional treatment landscape.
  • Patient-centric Approach: Patient-centricity is becoming increasingly important in healthcare, and CIC is no exception. Patients are actively seeking treatments that are convenient, easy to use, and have minimal side effects. New producers of chronic idiopathic constipation solutions can develop patient-centric products that prioritize patient comfort and compliance, such as user-friendly formulations, patient-friendly packaging, and novel administration routes, which can differentiate their products in the market.

Chronic idiopathic constipation treatment market forecast by Fact.MR

Country-wise Analysis

What is the Demand Outlook for Chronic Idiopathic Constipation Treatment Procedures in the United States?

“Presence of Key Market Players and Rising Prevalence of Constipation among All Age Groups”

Rising prevalence of chronic constipation, the presence of key market players, and increasing investments in healthcare are the key factors driving sales of chronic idiopathic constipation treatment solutions.

  • Constipation is a common type of illness in Americans of all ages, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • Approximately 16 out of every 100 people have constipation in the United States. Therefore, it is anticipated that the demand for chronic idiopathic constipation treatment solutions is likely to rise during the forecast period.

What is Driving the Sales of Chronic Idiopathic Constipation Solutions in Germany?

“Well-established Healthcare & Pharma Facilities”

Germany is one of the countries with advanced healthcare systems in Europe. In recent years, there has been growing interest in novel treatment options for constipation. Advancements in constipation treatment options are expected to drive the growth of the German market for chronic idiopathic constipation treatments.

The prosecretory agents such as lubiprostone and linaclotide, which increase intestinal fluid secretion and promote bowel movement, have shown promising results in clinical trials and are gaining popularity among healthcare professionals. Thus, developments in drug production are expected to generate profitable opportunities for CIC drug manufacturers.

How is Demand for Chronic Idiopathic Constipation Drugs Progressing in Japan?

“High Prevalence of Constipation in Senior Population”

Constipation is a common gastrointestinal disorder that affects millions of people in Japan. One of the key factors driving the constipation treatment market in Japan is the rising prevalence of constipation among the ageing population.

Japan is experiencing demographic shifts with the rising rate of the ageing population. There has been a higher incidence of constipation due to age-related changes in bowel function, medication use, and comorbidities. This is further increasing the demand for effective constipation treatments in the country.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Category-wise Analysis

Which Types of Drugs are Most Popular in This Space?

“Laxatives Considered Most Effective Drugs for Constipation Treatment”

Laxatives are substances that affect the intestines in such a way as to induce bowel movement. When used with or without electrolytes, polyethylene glycol is more effective than a placebo for the treatment of functional constipation. Constipation is treated with methylcellulose fiber, which also helps to maintain regular bowel movements.

Methylcellulose (Citrucel) belongs to the class of laxatives that create large stools. It increases the volume of feces, which improves intestinal motility and controls bowel movements. It is used in conjunction with dietary changes and other therapy to treat constipation and restore and maintain bowel regularity. Thus, the demand for constipation laxatives is increasing rapidly.

Competitive Landscape

According to Fact.MR, a market research and competitive intelligence provider, key players in the chronic idiopathic constipation treatment market are focused on developing technologically advanced solutions, introducing new design products, obtaining regulatory clearances, and partnering and acquiring other businesses.

The FDA approval for newly discovered medications is currently being sought by leading companies in the chronic idiopathic constipation treatment market. Over the forecast period, obtaining FDA approval is anticipated to continue to be one of the primary areas of attention for the producers of medications for chronic idiopathic constipation.

The FDA has just given the all-clear to several medications.

  • An osmotic laxative created by Braintree Laboratories (Sebela) was given FDA approval in February 2020 to treat adults with chronic idiopathic constipation.
  • Ironwood Pharmaceuticals, Inc. reported in April 2020 that the USPTO has granted certificates of approval for patent applications relating to the formulation of the 72 mcg dose of LINZESS.
  • The U.S. Food and Drug Administration granted Sebela Pharmaceuticals, Inc. permission to market Pizensy (lactitol) in March 2020.

Chronic Idiopathic Constipation Treatment Industry Research Segmentation

  • By Type :

    • Normal-transit Constipation
    • Slow-transit Constipation
  • By Therapy :

    • Pharmacological Therapies
    • Non-pharmacological Therapies
  • By Treatment :

    • Medication
    • Surgery
  • By Drug :

    • Serotonin-4 (5-Ht4) Receptor Agonist
    • Guanylate Cyclase-C Agonist
    • Laxatives
    • Stimulants
  • By Route of Administration :

    • Oral
    • Injectable
  • By End User :

    • Hospitals
    • Homecare
    • Specialty Clinics
  • By Region :

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

- FAQs -

The global chronic idiopathic constipation treatment market is valued at US$ 9.4 billion in 2023.

Global sales of chronic idiopathic constipation treatment solutions are set to increase at a CAGR of 7.5% from 2023 to 2033.

Demand for chronic idiopathic constipation treatment solutions is expected to reach US$ 19.7 billion by 2033.

Ironwood Pharmaceuticals, Inc., Sebela Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH are some of the leading companies in the market.

North America currently accounts for a leading position in the global market.

Chronic Idiopathic Constipation Treatment Market

Schedule a Call
Google translate